Actions in Vietnam

"We deeply thank the American people who have supported us through the PEPFAR program. This program has saved many people and given them a new life.  Many of us now have love, marriage and healthy, HIV-negative children.

Although we have made significant progress in Vietnam, we are very worried about the future and many people still do not have access to treatment. Current projections suggest that 150,000 people will be in need of ARV treatment in 2015.

 The high price of second-line treatments in addition to costly medicines for Hepatitis B and C place a heavy financial burden on our shoulders. Many of us will not be able to afford it.

This is why today we are sending letters to Abbott and the Ministry of Health. We need access to lower priced second-line treatment. We hope we will receive positive responses to our letters. Affordable second-line treatment is vital for the Vietnam HIV/AIDS community’s ability to continue to make progress fighting this disease."

-- Dong Duc Thanh, Vietnam Network of People Living with HIV


In Vietnam, Kaletra costs $2,280 ppy, nearly double the country’s 2010 per capita GDP of $1,191. Abbott’s high cost monopoly limits the ability of the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to expand access to treatment in Vietnam.

Signatories representing over 250 Vietnamese organizations sent a letter to Abbott requesting an open license that would enable Vietnam to provide affordable generics to its people. Additionally, the Vietnam Network of People Living with HIV sent a letter to the Ministry of Health requesting the government make use of any patents necessary to provide generic lopinavir + ritonavir.

Copy of letter sent to Abbott Laboratories requesting an open license with more than 50 signatories representing over 250 organizations (11/10/2011)

Copy of Abbott Laboratories' response letter to VNP+ (11/28/2011)

Copy of letter sent to Minister of Health requesting government use of patent


English | Vietnamese

Full statement of Dong Duc Thanh (VNP+)

English | Vietnamese

Also see the "PEPFAR Vietnam COP REPORT FY 2010" on Abbott's brand name lopinavir/ritonavir driving up the cost of the program.

Expanding Access to Treatment for Hepatitis C in Resource-LImited Settings: Lessons from HIV/AIDS (Clinical Infectious Diseases Advance Access) - March 19, 2012

Return to the Kaletra Campaign Homepage

Copyright © 2017 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.